COME-IN-CARE

COmpound 21 and MElatonin in CArdiovascular REmodeling

 Coordinatore CHARITE - UNIVERSITAETSMEDIZIN BERLIN 

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fräßdorf
Email: send email
Telefono: 4930450000000
Fax: 4930450000000

 Nazionalità Coordinatore Germany [DE]
 Totale costo 0 €
 EC contributo 121˙598 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-IEF-2008
 Funding Scheme MC-IEF
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-08-01   -   2011-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fräßdorf
Email: send email
Telefono: 4930450000000
Fax: 4930450000000

DE (BERLIN) coordinator 121˙598.20

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

melatonin    training    ras    compound    remodeling    angiotensin    indicate    group    activation    diseases    fibrosis    cv    hypertension    researcher    scientific    combination    at   

 Obiettivo del progetto (Objective)

'Cardiovascular (CV) diseases are the major source of morbidity and mortality in the EU with annual costs of € 169 billion. The control of hypertension and prevention of left ventricular (LV) hypertrophy and fibrosis, which could interrupt the CV continuum, still remain insufficient world-wide. A substantial part of current therapies modulate the renin-angiotensin system (RAS) and decrease the unfavorable stimulation of angiotensin type 1 receptors (AT1R). Results of the host group indicate that many of AT1R effects are opposed by type 2 receptor (AT2R) activation. AT2R are up-regulated in several pathologies, making targeting of AT2R effective specifically in disease. The investigation of long-term effects of direct AT2R activation on hypertension and CV remodeling was allowed only recently by the discovery of AT2R agonist, compound 21. Fellows results suggest, that the pineal hormone and antioxidant, melatonin, prevents fibrosis and can be especially useful in combination with RAS modulation. We aim to investigate the effects of 5-week administration of compound 21, melatonin and their combination in L-NAME hypertensive rats on CV remodeling and relevant protein expression pattern. Advanced, interdisciplinary techniques from physiology to molecular biology will be implemented. The findings should indicate whether the exciting AT2R targeting is a promising approach to CV diseases and whether the use of a novel drug combination can preserve myocardial structural homogeneity. This project will yield important scientific and clinical implications and provide an outstanding training, guaranteed by excellent researcher in charge. Proposed training will unfold researcher’s creativity, networking and other complementary skills and promote his scientific maturity and independence necessary to create an own research group. Possible reintegration of the researcher with his enhanced scientific output will increase the competitiveness in his country of origin.'

Altri progetti dello stesso programma (FP7-PEOPLE)

GENDERMASSCAREER (2011)

Mass Career Customization -a flexible career approach : effects on women's career advancement and wellbeing

Read More  

DINURU (2011)

The Synthesis and Evaluation of Organometallic Dinuclear Ruthenium Complexes as Anti-Cancer Drugs

Read More  

GREAT (2011)

Gaia Research for European Astronomy Training - ITN

Read More